ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DXRX Diaceutics Plc

137.00
-2.00 (-1.44%)
06 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -1.44% 137.00 136.00 138.00 139.00 137.00 139.00 90,695 10:39:15
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 23.7M -1.75M -0.0206 -66.50 117.84M

Diaceutics PLC Awarded UK Research Institute Grant Funding of £1m

05/12/2024 7:00am

RNS Regulatory News


RNS Number : 6548O
Diaceutics PLC
05 December 2024
 

Diaceutics awarded UK Research Institute Grant Funding of £1m

 

Belfast and London, 5 December 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that the Company has been awarded approximately £1m in grant funding from the United Kingdom Research Institute (UKRI) Strength in Places Fund, to further elucidate the gaps in clinical practices that need addressing so that all appropriate patients benefit from precision medicine in Northern Ireland/UK. An output of this grant is expected to be enhancements to Diaceutics' data products in 2025.

 

Diaceutics' is proud to be a partner with many great Northern Ireland institutions and companies that collectively support and enhance the Belfast medical & technology community, which is critical for sustainable talent development in the region.

 

The UKRI Strength in Places Fund, via its Wave 2 investment phase, will provide £34m to fund the Future Medicines Institute based at Queens University Belfast and its purpose will be to provide infrastructure & expertise to Northern Ireland based companies and to act as a research accelerator unit.

 

Ryan Keeling, Chief Executive Officer of Diaceutics, commented: "We are very grateful to the UKRI for awarding this funding, which we will deploy to support our R&D activities.  Initiatives such as this are very important and will help us progress our data products, clinical data & bioinformatics pipeline development, staff skills and apprenticeships development ".

 

Enquiries: 

Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 



Canaccord Genuity Limited (Nomad & Broker) 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFESFRLVIIS

1 Year Diaceutics Chart

1 Year Diaceutics Chart

1 Month Diaceutics Chart

1 Month Diaceutics Chart